Dose-Response Study of N,N-Dimethyltryptamine in Humans
1994/02/01 by Rick J. Strassman · 30 citations
Psychology · Pharmacology, Toxicology and Pharmaceutics · Neuroscience · #Psychedelics and Drug Studies #Forensic Toxicology and Drug Analysis #Neurotransmitter Receptor Influence on Behavior
paper · doi:10.1001/archpsyc.1994.03950020009001
Abstract
BACKGROUND: To begin applying basic neuropharmacological hypotheses of hallucinogenic drug actions to humans, we generated dose-response data for intravenously administered dimethyltryptamine fumarate's (DMT) neuroendocrine, cardiovascular, autonomic, and subjective effects in a group of experienced hallucinogen users. METHODS: Dimethyltryptamine, an endogenous mammalian hallucinogen and drug of abuse, was administered intravenously at 0.05, 0.1, 0.2, and 0.4 mg/kg to 11 experienced hallucinogen users, in a double-blind, saline placebo-controlled, randomized design. Treatments were separated by at least 1 week. RESULTS: Peak DMT blood levels and subjective effects were seen within 2 minutes after drug administration, and were negligible at 30 minutes. Dimethyltryptamine dose dependently elevated blood pressure, heart rate, pupil diameter, and rectal temperature, in addition to elevating blood concentrations of beta-endorphin, corticotropin, cortisol, and prolactin. Growth hormone blood levels rose equally in response to all doses of DMT, and melatonin levels were unaffected. Threshold doses for significant effects relative to placebo were also hallucinogenic (0.2 mg/kg and higher). Subjects with five or more exposures to 3,4-methylenedioxymethamphetamine demonstrated less robust pupil diameter effects than those with two or fewer exposures. CONCLUSIONS: Dimethyltryptamine can be administered safely to experienced hallucinogen users and dose-response data generated for several measures hypothesized under serotonergic modulatory control. Additional studies characterizing the specific mechanisms mediating DMT's biological effects may prove useful in psychopharmacological investigations of drug-induced and endogenous alterations in brain function.
Cited by
- Dose-Response Study of N,N-Dimethyltryptamine in Humans
- Psychiatry & the psychedelic drugs. Past, present & future
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
- Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose?effect study
- Dimethyltryptamine [wikipedia]
- The behavioral pharmacology of hallucinogens. [europepmc]
- Human hallucinogen research: guidelines for safety. [europepmc]
- When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor. [europepmc]
- Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. [europepmc]
- The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice. [europepmc]
- Neuropharmacology of N,N-dimethyltryptamine. [europepmc]
- Clinical applications of hallucinogens: A review. [europepmc]
- The serotonin 5-HT 2C receptor and the non-addictive nature of classic hallucinogens. [europepmc]
- Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. [europepmc]
- Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls. [europepmc]
- Effects of psilocybin therapy on personality structure. [europepmc]
- N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function. [europepmc]
- DMT Models the Near-Death Experience. [europepmc]
- Neural correlates of the DMT experience assessed with multivariate EEG. [europepmc]
- Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N , N -Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact. [europepmc]
- A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers. [europepmc]
- Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective. [europepmc]
- Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT. [europepmc]
- Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. [europepmc]
- Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience. [europepmc]
- The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. [europepmc]
- Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. [europepmc]
- Pharmacokinetics of N,N-dimethyltryptamine in Humans. [europepmc]
- Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. [europepmc]
- Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. [europepmc]
Related